Upstream Bio Reports Third Quarter Financial Results
Upstream Bio reported its third-quarter financial results, highlighting a net loss of $41.2 million. The company's revenue for the period was $0.4 million, missing analyst expectations by $0.08 million. Despite the quarterly loss, Upstream Bio maintains a significant liquidity position with $207.4 million in cash, cash equivalents, and short-term investments as of September 30, 2026. The company's market performance has recently been influenced by positive clinical developments, specifically regarding Phase 2 data for severe asthma treatments.
Tickers: $UPB
Topics: cash position clinical trial data earnings miss net loss